Proteolytic cleavage of the amyloid precursor protein (APP) by the two proteases α-and β-secretases controls the generation of the amyloid β peptide (Aβ), a key player in Alzheimer's disease pathogenesis. The α-secretase ADAM10 and the β-secretase BACE1 have opposite effects on Aβ generation and are assumed to compete for APP as a substrate, such that their cleavages are inversely coupled. This concept was mainly demonstrated in studies using activation or overexpression of α-and β-secretases. Here, we report that this inverse coupling is not seen to the same extent upon inhibition of the endogenous proteases. Genetic and pharmacological inhibition of ADAM10 and BACE1 revealed that the endogenous, constitutive α-secretase cleavage of APP is largely uncoupled from β-secretase cleavage and Aβ generation in neuroglioma H4 cells and in neuronally differentiated SH-SY5Y cells. In contrast, inverse coupling was observed in primary cortical neurons. However, this coupling was not bidirectional. Inhibition of BACE1 increased ADAM10 cleavage of APP, but a reduction of ADAM10 activity did not increase the BACE1 cleavage of APP in the neurons. Our analysis shows that the inverse coupling of the endogenous α-and β-secretase cleavages depends on the cellular model and suggests that a reduction of ADAM10 activity is unlikely to increase the AD risk through increased β-secretase cleavage.
Introduction
Alzheimer's disease (AD) is a neurodegenerative disorder which causes progressive cognitive decline. A central player in AD pathogenesis is the amyloid β peptide (Aβ), which forms toxic oligomeric aggregates leading to neurodegeneration (for review see Hardy and Selkoe, 2002; Haass and Selkoe, 2007; Laferla et al., 2007) . The Aβ peptide derives from proteolytic processing of the type I membrane protein amyloid precursor protein (APP) by two protease activities referred to as β-and γ-secretases. β-secretase, which is the aspartyl protease BACE1 (Vassar et al., 1999) , cleaves in the ectodomain of APP at the N-terminus of the Aβ domain. As a result the large APP ectodomain (APPsβ) is released from cells. A short C-terminal fragment of APP (C99) remains in the membrane and undergoes subsequent processing by the γ-secretase protease complex (De Strooper et al., 1998) . This cleavage occurs at the C-terminus of Aβ and leads to Aβ secretion.
A third protease activity, called α-secretase, cleaves APP within the Aβ domain, and thus, has the potential to prevent Aβ generation (for a review see Lichtenthaler, 2011a). Similar to BACE1-cleavage, α-cleavage occurs within the ectodomain of APP close to the membrane and leads to the secretion of the APP ectodomain (APPsα). α-secretase cleavage occurs constitutively and is mediated by the metalloprotease ADAM10 (Jorissen et al., 2010; Kuhn et al., 2010; Postina et al., 2004) . Additionally, the α-secretase cleavage can be pharmacologically increased above its constitutive level, which is referred to as regulated α-secretase cleavage. In contrast to the constitutive α-cleavage, the regulated process can be mediated by different proteases, including ADAM10 and ADAM17 (for review see Lichtenthaler, 2011b) .
Several previous studies showed that a pharmacological activation of α-secretase, in particular by phorbol esters and muscarinic agonists, increased the α-secretase cleavage and reduced Aβ levels (e.g. Amtul et al, 2010; Caccamo et al., 2006; Donmez et al., 2010; Fu et al., 2009; Hung et al., 1993; Kim et al., 2009; Nitsch et al., 1992; Skovronsky et al., 2000; Tachida et al., 2008) , suggesting that α-and β-secretase cleavages are inversely coupled. Likewise, overexpression of ADAM10 in a mouse
